An Australian-developed therapy to treat hereditary angioedema (or H-A-E) is now part of the Pharmaceutical Benefits Scheme.
H-A-E is a rare and chronic condition found in one in 50,000 Australians who experience unpredictable swelling in abdomen, larynx, face, and limbs, and the condition is life-threatening.
The new treatment called Andembry is applied once a month and available as a pre-filled pen.
The Wire’s Eduardo Jordan started asking Professor of Immunology and Allergy at Western Sydney University Connie Katelaris to explain more about hereditary angioedema.
Image: Person holding an insulin injection | Unsplash
Produced By: Eduardo Jordan
Featured In Story: Connie Katelaris – Professor of Immunology and Allergy at Western Sydney University
First aired on The Wire, Tuesday, 7 April 2026